ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1390

Hidradenitis Suppuritiva Is Associated with Inflammatory Eye Disease

Abrahim U. Syed1, Didem Uzunaslan2, Careen Y. Lowder3, Sunil Srivastava3, Juan J. Maya1 and Rula A Hajj-Ali4, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Cleveland, OH, 3Cole Eye Institute, Cleveland Clinic, Cleveland, OH, 4Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Eye disease, inflammatory bowel disease (IBD), skin and uveitis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Hidradenitis Suppurativa (HS) is an inflammatory skin condition that can cause profound morbidity. Patients can present with recurrent nodules, sinus tract formation, abscesses and/or scarring, mainly affecting intertriginous skin areas. A variety of inflammatory disorders have been associated with HS, such as inflammatory bowel disease (IBD) and spondyloarthropathies. Case reports have documented coexistence between HS and inflammatory eye disease (IED), but associations have not been described. Herein, we aimed to assess the types of IED associated with HS, risk factors for developing IED in patients with HS, and treatment outcomes. 

Methods:

Case identification was performed by including all cases within Cleveland Clinic Health System with a diagnosis of HS (ICD code 705.83) and any IED. Using this strategy, 483 patients were identified. With Cleveland Clinic electronic medical records, a retrospective chart review was done to identify demographics, IED patterns, associated conditions, treatments and outcomes. Ophthalmologic notes were reviewed by an independent ophthalmologist to ensure accuracy of IED diagnosis. Patients with episcleritis and sicca were excluded given their prevalence in the general population. Only those with chronic IED were included. A total of 20 patients with HS and IED met these criteria. Qualitative variables were described with measures of frequency.

Results:

16 patients were female (80%). 12 were African American (60%) and 7 Caucasian (35%). HS was diagnosed before IED in 11 patients (55%). Mean age when HS was diagnosed was 42.15; mean age when IED was diagnosed was 43.65.

13 patients had uveitis (65%), 6 had scleritis (30%) and 1 had peripheral ulcerative keratitis. 8 patients (40%) had a co-morbid IBD: 5 with Crohn’s disease, 1 with ulcerative colitis, and 2 were undifferentiated. RA and common variable immunodeficiency were each diagnosed in 2 patients. There was 1 patient for each of the following conditions: sarcoidosis, AS, psoriasis, Behcet’s disease, multiple sclerosis, SLE, lymphoma, and colon cancer.

Table 1: Treatment of IED with a diagnosis of HS

Treatment

Number of Patients

Number Achieving Remission

Topical Steroid

17

6 (35%)

Systemic Steroid

7

1 (14%)

Infliximab

4

3 (75%)

Adalimumab

4

2 (50%)

Methotrexate

7

2 (29%)

Periocular steroid injection

1

0

Conclusion:

HS should be included in the etiology of IED. Female gender and African American ethnicity are common in patients with both IED and HS. The pattern of IED most associated with HS was uveitis followed by scleritis. Among the co-morbidities, IBD is the most prevalent, especially the subset of Crohn’s disease. While topical steroid remains first-line treatment, systemic immunosuppressive agents show promise for refractory eye disease, particularly anti-TNF-alpha biologics among this study group.


Disclosure: A. U. Syed, None; D. Uzunaslan, None; C. Y. Lowder, None; S. Srivastava, None; J. J. Maya, None; R. A. Hajj-Ali, None.

To cite this abstract in AMA style:

Syed AU, Uzunaslan D, Lowder CY, Srivastava S, Maya JJ, Hajj-Ali RA. Hidradenitis Suppuritiva Is Associated with Inflammatory Eye Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/hidradenitis-suppuritiva-is-associated-with-inflammatory-eye-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hidradenitis-suppuritiva-is-associated-with-inflammatory-eye-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology